Inquire About a Product| Product: | Aceclofenac | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Catalog Number: | 4661 | ||||||||
| CAS Number: | 89796-99-6 | ||||||||
| Pricing: |
|
||||||||
| Formula: | C16H13Cl2NO4 | ||||||||
| Chemical Purity: | >98% | ||||||||
| Molecular Weight: | 354.18 | ||||||||
| Structure: |
|
||||||||
| Appearance: | Solid | ||||||||
| Category: | Unlabeled Reference Standards | ||||||||
| Stability: | Stable under recommended storage conditions. | ||||||||
| Storage: |
Keep container tightly closed in a dry and well-ventilated place |
||||||||
| Transportation: |
IATA: Hazard Class: 6.1; UN Number: UN2811; Packing Group:III; Shipping Name: Toxic solid, organic, n.o.s. (Aceclofenac) |
||||||||
| Literature References: |
González EL, et al., Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthritis Rheum., (2010); Alvarez-Soria MA, et al., Long-term NSAID treatment directly decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarth. Cartil. 12th ed.,, 1484-1493, (2008); Yamazaki R, et al. , Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells. J. Pharmacol. Exp. Ther. 2nd ed., 289, 676-681, (1999); Merck 14,22 |
||||||||
| MSDS: | |||||||||
| Description: |
Non-steroidal, anti-inflammatory drug (NSAID), with selectivity for COX-2 over COX-1 |